INFLAZYME BEGINS TRIAL OF ASTHMA DRUG

A A

Inflazyme has initiated a Phase IIb study comparing the effect of its drug candidate IPL512-602 with placebo in patients suffering from moderate-to-severe asthma.

The eight-week study will assess the efficacy and safety of 20 mg of IPL512-602 given once daily as an oral asthma medication. Approximately 200 male and female subjects, suffering from asthma symptoms and attacks despite taking their regular medications, will be enrolled in the study.

The drug candidate represents a new therapeutic approach that focuses on improving asthma control and reducing asthma symptoms.